The Translational Research Group on Urology, haded by Francisco Gómez Veiga, demonstrates the benefits of focal therapy as a treatment for prostate cancer.
The Translational Research Group of Urology (GITUR) (Grupo de investigación traslacional de urología – GITUR) of the Institute of Biomedical Research of Salamanca (Instituto de Investigación Biomédica de Salamanca – IBSAL) headed by Francisco Gómez Veiga – Professor of the Faculty of Medicine and Head of the Urology Department of the Salamanca University Healthcare Complex – has proved the efficacy of a new treatment against prostate cancer. Focal therapy has important advantages in achieving a greater ability to control the disease and, in turn, shows a significant reduction in side effects compared to other therapies. One of the main conclusions drawn from the research concerns the predictable evolution of treatments for this disease, which will be more specific in relation to the specific peculiarities of each patient and type of tumor.
More information at Comunicación Universidad de Salamanca
News published in the media: